Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (1169)	9/16/1999 12:04:00 AM
From: JF Quinnelly	Read Replies (1) \| Respond to of 3202

We are already having INCY October. I don't think that it's time to back up the truck, but I might add a couple of shares here.

To: sim1 who wrote (1169)	9/19/1999 4:48:00 PM
From: LLCF	Read Replies (1) \| Respond to of 3202

This should be interesting... the microarray collaborations we were expecting are coming out despite the patent issue remaining unresolved! Also looks like this may be barter? Naysayers would have a field day with that.... Company Press Release Incyte and Huntsman Cancer Institute Announce Partnership to Study Colon Cancer Genetics Agreement to Include Access to LifeSeq Gold PALO ALTO, Calif.--(BW HealthWire)--Sept. 18, 1999--Incyte Pharmaceuticals, Inc. (Nasdaq:INCY - news) and the Huntsman Cancer Institute (HCI) today announced a two-year collaboration to study the role of genes in the diagnosis, prevention, and treatment of cancer. As a part of a long-term strategy, Incyte is now broadening its partnerships to include academic research institutions like the HCI in addition to alliances with pharmaceutical and biotechnology companies. Under this agreement, HCI will be the first academic institution to access Incyte's LifeSeq Gold® database, the world's most extensive collection of human genetic information. In addition, HCI will use Incyte's state-of-the-art microarrays and microarray data management software. These research tools help scientists analyze how genes function and identify which genes make the best drug targets. Incyte will work closely with HCI scientists and receive access to high quality tissue and tumor samples as well as research findings from HCI's colon cancer program. The partnership will provide opportunities to analyze the genetics of cancer in families with a high risk of developing inherited forms of cancer. Unique resources available to Incyte and HCI researchers will include high-risk cancer care clinics, the Utah Population database, and the Utah Cancer registry. ''This is our first step toward broadening the application of LifeSeq Gold® into the scientific community. Over the next several years, we would like to see LifeSeq Gold® on every desktop throughout the biomedical research community,'' said Randy Scott, President and Chief Scientific Officer of Incyte. ''HCI is a pre-eminent research institution for cancer. For us, this is a great opportunity to work with their scientists and access their tissue biology and genetic information. In turn, we will provide HCI with research tools that dramatically speed the development of innovative cancer treatments.'' ''One of our key research targets is colon cancer. Incyte's microarrays will help researchers determine whether a patient's colon cancer tissue expresses the genes that make cancer resistant to widely used chemotherapy drugs. Ultimately, we can improve the doctor's ability to rule out less effective treatments, and select the best treatments quickly,'' said Dr. Raymond White of the Huntsman Cancer Institute. About Incyte Pharmaceuticals, Inc. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, and related reagents and services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's website at www.incyte.com. About the Huntsman Cancer Institute The Huntsman Cancer Institute (HCI) at the University of Utah was created through the generosity of the Huntsman family to find the causes of cancer, develop new and better treatments, and prevent people from ever developing cancer. HCI is committed to discovering genetic and molecular solutions that will interrupt cancer development in its earliest stages and provide innovative therapies for later-stage cancers. Under the guidance of Dr. Raymond White, a renowned geneticist and pioneer in gene mapping and identification, HCI ranks among the best and most prestigious research institutions across the nation. In 1991, White discovered the APC (Adenomatous Polyposis Coli) tumor suppressor gene, which significantly advanced understanding of the initial progression of colon cancer. For more information about HCI, visit the website at www.hci.utah.edu. Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements. DAK